Primary Myelofibrosis — A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis
Citation(s)
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis